Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Direct Dial: 800-772-6436
Fax : 866-292-6436

Submitted by:
Phuong Khanh Morrow, MD, FACP
Executive Medical Director
Amgen Inc.
One Amgen Center Drive, MS 38-2-B
Thousand Oaks, CA 91320-1799
pmorrow@amgen.com

**Date of request: October 7, 2016**
**NCCN Guidelines Panel: Multiple Myeloma Panel**

On behalf of Amgen Inc., I respectfully request the NCCN Multiple Myeloma panel members to review the enclosed information on the use of Kyprolis® (carfilzomib) in combination with dexamethasone, approved by the FDA for the treatment of relapsed or refractory multiple myeloma patients.

We are providing information in order to correct a footnote contained within Myeloma Therapy (MYEL-D) section of the updated Guidelines (version V1.2017). The footnote is not accurate and states: "The dose of carfilzomib used in the ENDEAVOR trial is higher than the dose approved by the FDA".

**FDA Approval:** Kyprolis® (carfilzomib) for Injection is approved by the US FDA:

- in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
- as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[1]

**Dosing of Kyprolis® in combination with dexamethasone:**
For the combination regimen with dexamethasone, administer Kyprolis intravenously as a 30-minute infusion on two consecutive days, each week for three weeks followed by a 12-day rest period. Administer Kyprolis by 30-minute infusion at a starting dose of 20 mg/m$^2$ in Cycle 1 on Days 1 and 2. If tolerated, escalate the dose to 56 mg/m$^2$ on Day 8 of Cycle 1.

**Supporting Documentation:** The current prescribing information is being been submitted in support of this request.

The FDA approved labeling for Kyprolis reflects the FDA approved dosing studied in the ENDEAVOR trial as described above. Amgen is concerned that the inaccurate footnote could lead to prescriber confusion about the safe and effective dosing of Kyprolis® or to inaccurately conclude that Amgen encourages use of Kyprolis in a way inconsistent with its FDA approval.

Sincerely,

Phuong Khanh Morrow, MD, FACP
Executive Medical Director